BG1461U1 - Compositions of an antiparasitic remedy - Google Patents

Compositions of an antiparasitic remedy Download PDF

Info

Publication number
BG1461U1
BG1461U1 BG1949U BG194911U BG1461U1 BG 1461 U1 BG1461 U1 BG 1461U1 BG 1949 U BG1949 U BG 1949U BG 194911 U BG194911 U BG 194911U BG 1461 U1 BG1461 U1 BG 1461U1
Authority
BG
Bulgaria
Prior art keywords
characterized
drug compositions
compositions according
used
antiparasitic drug
Prior art date
Application number
BG1949U
Other languages
Bulgarian (bg)
Inventor
Мариана Караниколова
Тодорка Кърпачева
Original Assignee
"Ендектовет" Еоод
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by "Ендектовет" Еоод filed Critical "Ендектовет" Еоод
Priority to BG1949U priority Critical patent/BG1461U1/en
Publication of BG1461U1 publication Critical patent/BG1461U1/en

Links

Abstract

The utility model covers the compositions of an antiparasitic remedy to combat helminthozoonoses used in veterinary medicine. Usage of this remedy in veterinary medicine will provide a new solution of the major problems existing in traditional prophylaxis of helminthozoonoses. The compositions of the antiparasitic remedy contain, in weight percentage: doramectin as active substance from 0,005 to 25,0

Description

Technical field

The utility model relates to compositions of an antiparasitic drug for the control of helminth zoonoses, which are used in veterinary medicine.

BACKGROUND OF THE INVENTION

Zoonotic diseases, common to animals and humans, are known to become increasingly relevant. This is due to the intensification of human contact with domestic and free-living animals for economic, recreational and other reasons. In the world of health science and practice it is accepted by the term "zoonosis" to mean diseases that affect both animals and humans. The importance of the issue of zoonoses is rooted in their particularly high social health importance. The question of the role of animals in zoonoses is not limited to the existing etiological community of the diseases caused. The key here is the crucial involvement of animals in the transmission and maintenance of zoonoses. They are the source of the infectious agent for humans and the reservoir of infection. Directive 2003/99 / EC of the European Parliament states that the protection of human health from diseases and infections transmitted directly or indirectly by human animals (zoonoses) is of paramount importance. Zoonoses transmitted through sources other than food, in particular through populations of live animals and pets, are also of major concern.

Zoonotic heartworm is known worldwide, except in the Arctic and northern temperate regions. It is also known as canine nematode disease in dogs - caninae heartworm disease. Worldwide, dog numbers make up over 20% of the population, with the tendency to increase.

It is known to use various formulations of antiparasitic drugs in the form of tablets, granules, spot on and the like. for the prevention of dirofilariosis in dogs (US 3856971, US 7064108, US 6469067,

EP 1522219, US 6426333).

Antiparasitic drugs are known, such as monovalent tablet formulations containing avermectin or ivermectin. A major problem with their application is the observed side effects in some dog breeds.

Polyvalent (containing two or more active substances) tablet formulations are known in which one or more antiparasitic substances against other types of parasites are included in addition to the active substance against the heartworm. For the prevention of heartworm disease, they should be administered monthly, while treatment with other parasites requires treatment every two or three months. Monthly treatment with this type of tablet unnecessarily burdens the animal body with antiparasitic substances intended to control other parasites, while at the same time causing resistance (resistance) of the parasites to them, which leads to a decrease in their effectiveness and a high cost of prevention.

Granular antiparasitic forms are known to be administered with drinking water or animal feed. The downside to them is the inability to control the amount of consumption. It is possible not to consume the specified amount and thus not to take the entire dose of the product, which leads to poor efficacy of these forms.

The use of absorbable shapes is known by spot spot deposition. Problems are expressed in the occurrence of skin-allergic reactions at the site of application, resulting in severe itching and redness; re-treatment, in cases of frequent exposure to the body of water, which increases the cost of treatment; increased risk of toxicological effects resulting from the product falling on the skin, eyes and visible mucous membranes of adults or children in contact with treated animals.

The technical nature of the utility model

The essence of the utility model are formulations of an antiparasitic drug for the control of helminth zoonoses intended for veterinary medicine.

1461 Ul

The drug thus obtained provides a new solution for the control of animal heartworm and to overcome the deficiencies identified in the prior art for the traditional prevention of helminthiasis in animals in veterinary medicine. The formulations obtained according to the utility model are included in wt. %: doramectin active substance from 0.005 to 25.0; diluents (diluents) from 80.0 to 90.0 (lactose monohydrate, wheat starch and microcrystalline cellulose); binders from 1.0 to 10.0 (hydroxypropylcellulose, pregelatinized starch and polyvinylpyrrolidone); antioxidants from 0.01 to 3.0 (butyl hydroxytoluene, butyl hydroxyanisole, citric acid and vitamin C); disintegrants from 0.1 to 5.0 (wheat starch, hydroxypropyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, sodium lauryl sulfate, polyethylene glycol 6000); lubricants, anti-adhesives and glidants from 0.1 to 0.5 (magnesium stearate, talc, colloidal silica); flavoring substances from 0,001 to 1,0 (of natural or synthetic origin, in the form of powder or liquid, soluble in water, ethanol or oil, flavored with ham, meat, bacon, chicken, veal, liver and sausage).

The compositions are stable and are administered in the form of a solid dosage form.

Examples of implementation of the utility model

The following examples illustrate the effect of the invention, but should not be construed to limit it in any way.

The compositions of the drug for the prevention of helminth zoonoses are described in Examples 1 to 5.

The sequence of technological operations for the preparation of the anti-parasite drug is as follows:

1. Sieving, weighing and mixing of diluting substances.

2. Preparation of granulating solutions.

3. The mixture of item 1 is granulated and dried.

4. Lubricants and disintegrants are added to the mixture of item 3.

5. The mixture of item 4 is tableted.

Depending on the type of animal and the severity of the helminthosis, one of the listed compositions is individually administered and administered.

EXAMPLE 1:

Composition Quantity,% Doramectin 0.005 - 25.0 Hydroxypropylcellulose 1.0 -10.0 Citric acid 0.01 - 3.0 Polyethylene glycol 6000 0.1 - 5.0 Lubricants and glidants 0.1 - 5.0 Flavorings 0.001 - 1.0 Diluting substances 80.0 - 90.0

EXAMPLE 2:

Composition  Quantity,% Doramectin 0.005 - 25.0 Pre-gelatinized starch 1.0 -10.0 Butyl hydroxytoluene 0.01 - 0.5 Sodium lauryl sulfate '0.1 - 5.0 Lubricants and glidants 0.1 - 5.0 Flavorings I 0.001 - 1.0 Diluting substances ! 80,0- 90,0 EXAMPLE 3: Composition <Quantity,% Doramectin '0.005 - 25.0 Polyvinylpyrrolidone 1.0 -10.0 Butyl hydroxyanisole  0.01 - 0.5 Microcrystalline cellulose 0.1 - 5.0 Lubricants and glidants ; 0.1 - 5.0 Flavorings 0.001 - 1.0

Diluting substances 80.0 - 90.0 EXAMPLE 4: Composition Quantity,% Doramectin 0.005 - 25.0 Polyvinylpyrrolidone 1.0 -10.0 Vitamin C 0.1 - 2.0 Microcrystalline cellulose 0.1 - 5.0 Lubricants and glidants 0.1 - 5.0

Flavorings i 0,001-1,0

Diluting substances

80.0 - 90.0

EXAMPLE 5:

Composition Quantity,% Doramectin 0.005- 25.0 Polyvinylpyrrolidone 1.0 -10.0 Butyl hydroxyanisole 0.01 - 0.5 Wheat starch 0.1 - 5.0 Lubricants and glidants 0.1 - 5.0 Flavorings 0.001- 1.0 Diluting substances 80,0- 90,0 1 ......_ '

The results of the in vitro and in vivo studies performed with the described compositions in Examples 1 to 5 suggest that the compositions used exhibit a distinct microfilaricidal activity.

The use of this drug in veterinary medicine provides a new solution to the major problems that exist in the traditional prophylaxis of zoonotic helminthoses.

Claims (8)

1. Antiparasitic drug compositions characterized in that they contain by weight. %: active substance from 0.005 to 25.0; diluents from 80.0 to 90.0; granulating agents from 1.0 to 10.0; antioxidants from 0.01 to 3.0; disintegrants from 0.1 to 5.0; lubricants, anti-caking and glidants from 0.1 to 0.5; flavorings from 0.001 to 1.0.
Antiparasitic drug compositions according to claim 1, characterized in that doramectin is used as the active ingredient.
Antiparasitic drug compositions according to claim 1, characterized in that lactose monohydrate, wheat starch and microcrystalline cellulose are used as diluents.
Antiparasitic drug compositions according to claim 1, characterized in that hydroxypropylcellulose, pregelatinized starch and polyvinylpyrrolidone are used as binders (granulating).
Antiparasitic drug compositions according to claim 1, characterized in that butyl hydroxytoluene, butyl hydroxyanisole, citric acid and vitamin C are used as antioxidants.
Antiparasitic drug compositions according to claim 1, characterized in that wheat starch, hydroxypropyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, sodium lauryl sulfate, polyethylene glycol 6000 are used as disintegrants.
Antiparasitic drug compositions according to claim 1, characterized in that magnesium stearate talc, colloidal silica, is used as lubricants, anti-caking agents and glidants.
Antiparasitic drug compositions according to claim 1, characterized in that the flavoring substances are of natural or synthetic origin, in the form of powder or liquid, soluble in water, ethanol or oil, flavored with ham, meat, bacon, chicken , beef, liver and sausage.
BG1949U 2011-03-18 2011-03-18 Compositions of an antiparasitic remedy BG1461U1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BG1949U BG1461U1 (en) 2011-03-18 2011-03-18 Compositions of an antiparasitic remedy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BG1949U BG1461U1 (en) 2011-03-18 2011-03-18 Compositions of an antiparasitic remedy

Publications (1)

Publication Number Publication Date
BG1461U1 true BG1461U1 (en) 2011-07-29

Family

ID=45877083

Family Applications (1)

Application Number Title Priority Date Filing Date
BG1949U BG1461U1 (en) 2011-03-18 2011-03-18 Compositions of an antiparasitic remedy

Country Status (1)

Country Link
BG (1) BG1461U1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3856971A (en) * 1971-07-20 1974-12-24 E Friedheim Method of combating filariasis in dogs
US6426633B1 (en) * 1999-06-18 2002-07-30 Danfoss Drives A/S Method for monitoring a rotational angle sensor on an electrical machine
US6469067B1 (en) * 1999-11-25 2002-10-22 Novartis Ag Combinations
EP1522219A1 (en) * 1998-11-19 2005-04-13 Pfizer Inc. Antiparasitic formulations
US7064108B2 (en) * 2002-02-08 2006-06-20 Merck & Co., Inc. Topical ivermectin composition

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3856971A (en) * 1971-07-20 1974-12-24 E Friedheim Method of combating filariasis in dogs
EP1522219A1 (en) * 1998-11-19 2005-04-13 Pfizer Inc. Antiparasitic formulations
US6426633B1 (en) * 1999-06-18 2002-07-30 Danfoss Drives A/S Method for monitoring a rotational angle sensor on an electrical machine
US6469067B1 (en) * 1999-11-25 2002-10-22 Novartis Ag Combinations
US7064108B2 (en) * 2002-02-08 2006-06-20 Merck & Co., Inc. Topical ivermectin composition

Similar Documents

Publication Publication Date Title
Ungemach et al. Guidelines for prudent use of antimicrobials and their implications on antibiotic usage in veterinary medicine
Grave et al. Usage of veterinary therapeutic antimicrobials in Denmark, Norway and Sweden following termination of antimicrobial growth promoter use
Damm et al. Lying down and rolling behaviour in sows in relation to piglet crushing
Petherick et al. A review of the factors influencing the aggressive and agonistic behaviour of the domestic pig
BRPI0813235B1 (en) use of 2-deoxoparaherquamide and abamectin and anthelmintic composition
Biswas et al. Effect of feeding frequency on growth, survival and feed utilization in mrigal, Cirrhinus mrigala, and rohu, Labeo rohita, during nursery rearing
Swan The pharmacology of halogenated salicylanilides and their anthelmintic use in animals
Paull et al. The effect of a topical anaesthetic formulation, systemic flunixin and carprofen, singly or in combination, on cortisol and behavioural responses of Merino lambs to mulesing
EA030398B1 (en) Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
Remience et al. Effects of space allowance on the welfare of dry sows kept in dynamic groups and fed with an electronic sow feeder
MX2010005997A (en) Aminobenzamide derivatives as useful agents for controlling animal parasites.
HU0202825A2 (en) Oral treatment of companion animals with ectoparasiticidal spinosyns
Leathwick Managing anthelmintic resistance–parasite fitness, drug use strategy and the potential for reversion towards susceptibility
CN101549029A (en) Compound Chinese herbal medicine immunopotentiator for fish
AU2011299082B2 (en) Compounds as c-Met kinase inhibitors
US20050032719A1 (en) Anthelmintic formulations
WO2008128654A2 (en) Use of fungicides for treating fish mycoses
US7582612B2 (en) Multi-action anthelmintic formulations
Estrada-Angulo et al. Influence of level of zilpaterol chlorhydrate supplementation on growth performance and carcass characteristics of feedlot lambs
US20040244713A1 (en) Method for treating animals or masses of water with compositions comprising quinone compounds
Svendsen et al. Survival and growth of Lumbricus terrestris (Lumbricidae) fed on dung from cattle given sustained-release boluses of ivermectin or fenbendazole
Canul-Ku et al. Prevalence of cattle herds with ivermectin resistant nematodes in the hot sub-humid tropics of Mexico
EP0523523B1 (en) Anticoccidial compositions
CA2703261C (en) Antiparasitic agent for fish and method of controlling proliferation of fish parasites
CN101579044A (en) Chinese medicinal herb additive for pregnant sow and application thereof